Advertisements


Loxo Loses Out Despite Signing Big Cancer Deal

Loxo Oncology has announced that it will be partnering with Bayer to develop and commercialize larotrectinib and LOXO-195. Investors seem to believe that Loxo would have been better on its own. At........»»

Category: blogSource: 247wallstNov 14th, 2017

A drugmaker that"s taking an unconventional approach to cancer drugs just got a $1.5 billion endorsement

Elaine Thompson/AP Bayer signed a partnership with cancer drugmaker Loxo Oncology in a deal that could be worth up to $1.5 billion.  Loxo is developing treatments that act on cancerous genet.....»»

Category: topSource: businessinsiderNov 14th, 2017

Loxo, Bayer to co-develop cancer drugs in up to $1.55 billion deal

Loxo Oncology Inc will collaborate with Germany's Bayer AG to develop and commercialize two of its cancer therapies......»»

Category: topSource: foxnewsNov 14th, 2017

Inova Health System inks $60 million proton therapy deal

Inova Health System plans to begin offering proton beam therapy at its Inova Schar Cancer Institute by 2020 after signing a $60 million contract for a proton system from Reston-based Ion Beam Applications S.A. The deal comes after Inova received r.....»»

Category: topSource: bizjournalsJul 7th, 2017

Celgene Acquires Company Investigating Cancer Warfare Drug

Juno Therapeutics stock jumped 27% after $9 billion deal was announcedCheck out Ken.....»»

Category: dealsSource: nytJan 22nd, 2018

Celgene Is Paying $9 Billion for Juno Therapeutics in Blockbuster Cancer Drug Deal

With Juno, Celgene will gain research into a novel class of t.....»»

Category: europeSource: fortuneJan 22nd, 2018

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

LONDON (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets......»»

Category: topSource: reutersJan 22nd, 2018

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

LONDON, Jan 22 (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets......»»

Category: topSource: foxnewsJan 22nd, 2018

Celgene diversifies portfolio with purchase of Juno Therapeutics

Celgene Corp. has agreed to acquire Juno Therapeutics Inc. for about $9 billion, or $87 a share. The deal bolsters Celgene’s portfolio of blood-cancer drugs. The announcement comes on the heels of a report that the two companies were finalizin.....»»

Category: topSource: bizjournalsJan 22nd, 2018

Celgene is buying the cancer-drug maker Juno Therapeutics for $9 billion (CELG, JUNO)

AP Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments, in a deal worth $9 billion. It's the second deal in .....»»

Category: topSource: businessinsiderJan 22nd, 2018

Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion (CELG, JUNO)

AP Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments in a deal worth $9 billion.  It's the second deal.....»»

Category: topSource: businessinsiderJan 22nd, 2018

Celgene to acquire Juno Therapeutics for $9 billion, or $87 a share

Celgene Corp. on Monday said it's reached a deal to buy Juno Therapeutics Inc., a biotech company developing cancer treatments, for $9 billion, or $87 a share in cas.....»»

Category: topSource: marketwatchJan 22nd, 2018

Celgene is reportedly in talks to buy a $5.5 billion cancer drugmaker (JUNO, CELG)

Reuters Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal materializes, it'd be the second in 2018 for the biot.....»»

Category: topSource: businessinsiderJan 17th, 2018

The hottest thing in cancer drug development is a takeover target again — here"s what you need to know about it (JUNO, CELG)

AP Biotech giant Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal goes through, it'd be the second deal in the past few months for companies working on treatments that.....»»

Category: topSource: businessinsiderJan 17th, 2018

Celgene in Talks to Buy Juno Therapeutics

Celgene Corp. is in talks to buy biotechnology company Juno Therapeutics Inc., just days after announcing another major deal to bolster its portfolio of blood-cancer drugs......»»

Category: smallbizSource: wsjJan 16th, 2018

Celgene is reportedly in talks to buy a $5.5 billion cancer drugmaker

Reuters Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal materializes, it'd be the second in 2018 f.....»»

Category: topSource: businessinsiderJan 16th, 2018

GAIL renegotiates long-term LNG purchase deal with Russia"s Gazprom

The deal signed in 2012 is a 20-year LNG sales and purchase agreement following the signing of an earlier basic framework agreement (BFA) by the two companies in May 2011.....»»

Category: topSource: business-standardJan 16th, 2018

After Beating Cancer, Bernstein Analyst Goes Full "Jerry McGuire"

After taking six months medical leave to deal his lymphoma, Inigo Fraser-Jenkins, the head of global quantitative strategy and European equity strategy at Bernstein Researc.....»»

Category: blogSource: zerohedgeJan 11th, 2018

Huawei CEO: U.S. consumer loses from failure to ink phone deal with wireless carrier

World's No. 3 phone maker dealt set.....»»

Category: topSource: usatodayJan 9th, 2018

Celgene Nears Deal to Buy Impact Biomedicines

Celgene is nearing a deal to buy cancer biotechnology concern Impact Biomedicines for as much as $7 billion, according to people familiar with the matter......»»

Category: smallbizSource: wsjJan 7th, 2018

Roche Bolsters Cancer Portfolio With $1.7 Billion Ignyta Deal

Roche has agreed to buy U.S. cancer-therapy company Ignyta for $1.7 billion, the Swiss drugmaker’s latest move to shore up its oncology portfolio as its best-selling treatment faces generic competition......»»

Category: smallbizSource: wsjDec 22nd, 2017